Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases SYDNEY, AUSTRALIA, Dec. 17, ...
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...
Jet lag is a temporary sleep disorder you can get after traveling quickly across multiple time zones. It happens because your internal body clock is not yet aligned with your new local time. So you ...
Many of us have experienced jet lag after a holiday. But did you know you can have social jet lag as well? This happens when ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback